A cost-effectiveness analysis for the updated COVID-19 vaccine prepared for the CDC’s vaccine panel shows cost savings from vaccinating people over age 65, and good value from vaccinating adults of all ages.
Tag: Qaly
New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.